ATNX Athenex Inc.

18
0  0%
Previous Close 18
Open
Price To Book 12.95
Market Cap 1,387,182,564
Shares 77,065,698
Volume 0
Short Ratio
Av. Daily Volume 521,819

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 preliminary data showed 50% PR and 50% SD among first 12 patients.
Oraxol
Breast cancer
Phase 1b data noted 2/6 and 3/6 PRs in first two cohorts.
Oraxol and CYRAMZA (Ramucirumab)
Gastric cancer
Phase 3 data released July 26, 2018. Primary endpoint met.
KX-01 (KX2-391) Ointment
Actinic keratosis
Phase 3 top-line data due August 2019.
Oraxol
Metastatic breast cancer
Clinical trials to commence 2019.
Oral Eribulin
Phase 1/2 initiation announced November 26, 2018.
Oraxol and pembrolizumab (Keytruda)
Solid Tumors
Phase 1 poster at ASCO June 1, 2019.
Oratecan (ASCO 2019)
Solid Tumors
Phase 1 preliminary data released May 3, 2019. 3/7 complete responses.
Oraxol
Angiosarcoma

Latest News

  1. Athenex Rallies on Positive Early Data on Psoriasis Candidate
  2. Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
  3. Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
  4. Athenex Provides an Update on its Chongqing API Plant
  5. Athenex to Present at the 2019 ASCO Annual Meeting
  6. Edited Transcript of ATNX earnings conference call or presentation 9-May-19 12:00pm GMT
  7. Athenex, Inc. (ATNX) Q1 2019 Earnings Call Transcript
  8. Athenex: 1Q Earnings Snapshot
  9. Why Bausch Health Companies, Aquantia, and Athenex Jumped Today
  10. Athenex just raised $100 million. Here's what it means
  11. Athenex Announces $100 Million Private Placement
  12. Hedge Funds Have Never Been This Bullish On Athenex, Inc. (ATNX)
  13. Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma
  14. Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019
  15. Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting
  16. Athenex Announces Appointment of John Koh as a New Board Member
  17. Weekly CEO Buys Highlight
  18. Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
  19. Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares
  20. Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited